Keros Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Keros Therapeutics, Inc. (KROS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $74.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-04
- Keros Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $74.80M.
- Keros Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$189.31M.
- Keros Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$156.57M.
- Keros Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$112.24M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $74.80M 10-K · filed 2026-03-04 |
| 2024-12-31 | -$189.31M 10-K · filed 2026-03-04 |
| 2023-12-31 | -$156.57M 10-K · filed 2025-02-26 |
| 2022-12-31 | -$112.24M 10-K · filed 2025-02-26 |
| 2021-12-31 | -$55.96M 10-K · filed 2024-02-28 |
| 2020-12-31 | -$31.90M 10-K · filed 2022-03-09 |
| 2019-12-31 | -$5.56M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |